The National Center for Advancing Translational Sciences (NCATS) awarded a $1,199,511 Project Grant (CFDA# 93.350) to L2 Diagnostics LLC, a for-profit limited liability company, to develop a novel microneedle patch delivery system for an mRNA-based malaria vaccine candidate called AGTRIO. The project aims to produce a microneedle patch formulation of the AGTRIO vaccine that can provide protection against malaria in a mouse model, as a precursor to future pre-clinical and human clinical studies. The microneedle patch delivery system is designed to address challenges with cold chain storage and deployment of mRNA vaccines in malaria-endemic, resource-poor regions. The project will run from Jun 1, 2024 to May 31, 2026.
Generated 1/28/25, 9:25 AM